Subgroups of patients with hematological neoplasms vs controls
| . | COVID-19 outcome . | Patients affected, N . | Controls affected, N . | Relative risk . | Confidence interval . |
|---|---|---|---|---|---|
| Lymphomas, all types (n = 16 577) | Infection | 122 | 77 | 2.75 | 1.60-5.49 |
| Symptomatic | 77 | 39 | 4.34 | 2.07-12.82 | |
| Hospitalized | 34 | 5 | 13.87 | 4.97-56.85 | |
| Severe | 25 | 4 | 12.06 | 4.03-48.47 | |
| Death | 13 | 2 | 15.13 | 3.68-46.29 | |
| Multiple myeloma, receiving treatment (n = 1014) | Infection | 16 | 3 | 4.65 | 1.57-17.73 |
| Symptomatic | 10 | 2 | 5.29 | 1.46-15.61 | |
| Hospitalized | 6 | 1 | 6.43 | 1.00-10.95 | |
| Severe | 6 | 1 | 6.67 | 0.98-11.43 | |
| Death | 4 | 0 | NA | — |
| . | COVID-19 outcome . | Patients affected, N . | Controls affected, N . | Relative risk . | Confidence interval . |
|---|---|---|---|---|---|
| Lymphomas, all types (n = 16 577) | Infection | 122 | 77 | 2.75 | 1.60-5.49 |
| Symptomatic | 77 | 39 | 4.34 | 2.07-12.82 | |
| Hospitalized | 34 | 5 | 13.87 | 4.97-56.85 | |
| Severe | 25 | 4 | 12.06 | 4.03-48.47 | |
| Death | 13 | 2 | 15.13 | 3.68-46.29 | |
| Multiple myeloma, receiving treatment (n = 1014) | Infection | 16 | 3 | 4.65 | 1.57-17.73 |
| Symptomatic | 10 | 2 | 5.29 | 1.46-15.61 | |
| Hospitalized | 6 | 1 | 6.43 | 1.00-10.95 | |
| Severe | 6 | 1 | 6.67 | 0.98-11.43 | |
| Death | 4 | 0 | NA | — |